$21.24
1.07% today
Nasdaq, Nov 26, 04:47 pm CET
ISIN
US0008991046
Symbol
ADMA
Sector
Industry

ADMA Biologics, Inc. Target price 2024 - Analyst rating & recommendation

ADMA Biologics, Inc. Classifications & Recommendation:

Buy
100%

ADMA Biologics, Inc. Price Target

Target Price $25.00
Price $21.47
Potential
Number of Estimates 4
4 Analysts have issued a price target ADMA Biologics, Inc. 2025 . The average ADMA Biologics, Inc. target price is $25.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 5 Analysts recommend ADMA Biologics, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the ADMA Biologics, Inc. stock has an average upside potential 2025 of . Most analysts recommend the ADMA Biologics, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 258.22 422.30
67.59% 63.54%
EBITDA Margin 11.60% 39.32%
155.07% 238.89%
Net Margin -11.90% 27.99%
76.49% 335.20%

4 Analysts have issued a sales forecast ADMA Biologics, Inc. 2024 . The average ADMA Biologics, Inc. sales estimate is

$422m
Unlock
. This is
10.32% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$430m 12.35%
Unlock
, the lowest is
$417m 8.93%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $258m 67.59%
2024
$422m 63.54%
Unlock
2025
$484m 14.71%
Unlock
2026
$623m 28.63%
Unlock
2027
$726m 16.55%
Unlock
2028
$923m 27.12%
Unlock

3 Analysts have issued an ADMA Biologics, Inc. EBITDA forecast 2024. The average ADMA Biologics, Inc. EBITDA estimate is

$166m
Unlock
. This is
34.87% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$171m 38.66%
Unlock
, the lowest is
$163m 32.41%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $30.0m 192.30%
2024
$166m 454.17%
Unlock
2025
$226m 35.87%
Unlock
2026
$279m 23.55%
Unlock
2027
$340m 22.12%
Unlock
2028
$461m 35.48%
Unlock

EBITDA Margin

2023 11.60% 155.07%
2024
39.32% 238.89%
Unlock
2025
46.57% 18.44%
Unlock
2026
44.73% 3.95%
Unlock
2027
46.87% 4.78%
Unlock
2028
49.95% 6.57%
Unlock

3 ADMA Biologics, Inc. Analysts have issued a net profit forecast 2024. The average ADMA Biologics, Inc. net profit estimate is

$118m
Unlock
. This is
78.57% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$118m 78.57%
Unlock
, the lowest is
$118m 78.57%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-30.7m 60.61%
2024
$118m 484.62%
Unlock
2025
$160m 35.33%
Unlock
2026
$209m 30.38%
Unlock
2027
$249m 19.20%
Unlock
2028
$376m 51.19%
Unlock

Net Margin

2023 -11.90% 76.49%
2024
27.99% 335.20%
Unlock
2025
33.02% 17.97%
Unlock
2026
33.47% 1.36%
Unlock
2027
34.23% 2.27%
Unlock
2028
40.71% 18.93%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.13 0.50
60.61% 484.62%
P/E 42.94
EV/Sales 12.08

3 Analysts have issued a ADMA Biologics, Inc. forecast for earnings per share. The average ADMA Biologics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$0.50
Unlock
. This is
78.57% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$0.50 78.57%
Unlock
, the lowest is
$0.50 78.57%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.13 60.61%
2024
$0.50 484.62%
Unlock
2025
$0.68 36.00%
Unlock
2026
$0.88 29.41%
Unlock
2027
$1.05 19.32%
Unlock
2028
$1.59 51.43%
Unlock

P/E ratio

Current 77.71 312.90%
2024
42.94 44.74%
Unlock
2025
31.73 26.11%
Unlock
2026
24.34 23.29%
Unlock
2027
20.42 16.11%
Unlock
2028
13.50 33.89%
Unlock

Based on analysts' sales estimates for 2024, the ADMA Biologics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

12.08
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
12.02
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 13.32 220.19%
2024
12.08 9.33%
Unlock
2025
10.53 12.82%
Unlock
2026
8.18 22.26%
Unlock
2027
7.02 14.20%
Unlock
2028
5.52 21.33%
Unlock

P/S ratio

Current 13.26 247.13%
2024
12.02 9.35%
Unlock
2025
10.48 12.82%
Unlock
2026
8.15 22.26%
Unlock
2027
6.99 14.20%
Unlock
2028
5.50 21.33%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today